Galapagos NV

Chart & performance

D1W1MN

P/E

5.02

P/S

1.45

EPS

4.87

Div yield, %

—

Shrs. gr., 5y

0.25%

Rev. gr., 5y

18.40%

Revenues

Net income

CFO

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

URL

https://www.glpg.com/

IPO date

May 06, 2005

Employees

1,233

Domiciled in

Incorporated in

Valuation

No data to show